他汀类药物摄入对肾结石形成的影响
该研究基于机构电子数据仓库,纳入2009至2011年新诊断高脂血症且从未使用他汀的101,259例患者,随访至2015年。结果显示,启用他汀治疗者新发结石风险显著低于未使用者,且有结石病史者保护效应更强。他汀治疗组血脂参数更低,但保护机制似乎独立于降脂效应。
要点
- 他汀治疗与新发结石风险降低显著相关,有结石病史者保护效应更强。
- 他汀治疗组低密度脂蛋白、甘油三酯、胆固醇均低于未治疗组,提示用药依从性良好。
- 他汀的结石保护机制似乎独立于其降脂效应。
核心结论
- 他汀类药物对尿路结石形成具有保护作用,但该保护机制似乎独立于其降脂效应。
研究设计与样本
- 回顾性队列研究,查询机构电子数据仓库,纳入2009至2011年新诊断高脂血症且从未使用他汀的101,259例患者,随访至2015年。
- 收集患者人口学特征、结石危险因素、处方数据及血清血脂值,评估他汀处方与新发症状性尿路结石的关系。
主要发现
- 47.8%的患者在研究期间接受了他汀处方。
- 他汀处方者年龄显著更大,更可能患有骨质疏松、偏瘫、行动不便,也更可能使用噻嗪类利尿剂。
- 无结石病史者中,启用他汀治疗者新发结石风险显著低于未使用者,该保护效应在有结石病史者中更强。
- 他汀治疗组低密度脂蛋白、甘油三酯、胆固醇水平更低,提示总体用药依从性良好。
临床怎么用
- 对于高脂血症患者,他汀治疗可能降低新发尿路结石风险,尤其是有结石病史者。
- 他汀的结石保护作用不应仅归因于降脂效果,临床决策时需考虑其独立于血脂的潜在获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine whether statin intake affects nephrolithiasis risk, and whether higher lipid levels correlate with stone risk. Dyslipidemia is a known independent risk factor for urolithiasis, and emerging evidence suggests common biological pathways. Previous work has suggested that statins protect against new stone formation, but these findings have not been verified by other investigators. METHODS: We queried our Institution's Electronic Data Warehouse for all patients who were newly diagnosed with hyperlipidemia between 2009 and 2011, and had never taken a statin drug. These patients' clinical outcomes were followed until 2015, to assess whether they had been newly prescribed statins and whether they had developed symptomatic urolithiasis. Patient demographics, stone risk factors, prescription data, and serum lipid values were collected. RESULTS: A total of 101,259 patients met inclusion criteria, 47.8% of whom received a statin prescription during the study period. Patients prescribed statins were significantly older, had a greater likelihood of osteoporosis, hemiplegia, immobility, and more likely to take a thiazide diuretic. Patients without a history of urolithiasis who were started on statin therapy were significantly less likely to develop new stones than patients not taking statins. This protective effect was even greater in patients with a history of stone disease. Lipid parameters (low-density lipoprotein, triglyceride, cholesterol) were lower in the statin-treated group, suggesting overall compliance with these medications. CONCLUSION: Our data confirm previous work that statins protect against urinary stone formation; however, the underlying mechanism seems to be distinct from statins' lipid-lowering effect.
引用
- Cohen AJ, Adamsky MA, Nottingham CU, et al. Impact of Statin Intake on Kidney Stone Formation. Urology. 2018. PMID: 29421299. doi:10.1016/j.urology.2018.01.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。